Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma

Published:2015-11-05 Issue:19 Volume:126 Page:2193-2201
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kiyasu Junichi¹²³,Miyoshi Hiroaki¹,Hirata Akie⁴,Arakawa Fumiko¹,Ichikawa Ayako¹,Niino Daisuke¹,Sugita Yasuo¹,Yufu Yuji³,Choi Ilseung⁵,Abe Yasunobu⁵,Uike Naokuni⁵,Nagafuji Koji⁶,Okamura Takashi⁶,Akashi Koichi⁷,Takayanagi Ryoichi²,Shiratsuchi Motoaki²,Ohshima Koichi¹

Affiliation:

1. Department of Pathology, Kurume University, School of Medicine, Kurume, Japan;

2. Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;

3. Department of Hematology, Iizuka Hospital, Iizuka, Japan;

4. Department of Geriatric Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;

5. Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan;

6. Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan; and

7. Department of Medicine and Biosystemic Science, Kyushu University Faculty of Medicine, Fukuoka, Japan

Abstract

Key Points PD-L1 expression is associated with poor prognosis in DLBCL. The double-staining technique is a useful method for identifying and distinguishing PD-L1+ DLBCL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/19/2193/1345194/2193.pdf

Reference39 articles.

1. Diffuse large B-cell lymphoma, not otherwise specified.;Stein,2008

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.;Coiffier;N Engl J Med,2002

3. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.;Habermann;J Clin Oncol,2006

4. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.;Freeman;J Exp Med,2000

5. PD-1 and its ligands in tolerance and immunity.;Keir;Annu Rev Immunol,2008

Cited by 376 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up;Clinical Lymphoma Myeloma and Leukemia;2024-02

2. Presence of Epstein–Barr virus (EBV) antigens detected by sensitive methods has no influence on local immune environment in diffuse large B cell lymphoma;Cancer Immunology, Immunotherapy;2024-01-27

3. Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma;Blood Advances;2024-01-23

4. Immune checkpoint blockade in hematological malignancies: current state and future potential;Frontiers in Oncology;2024-01-23

5. Activation of Notch-1 signaling pathway in macrophages to secrete PD-L1 and regulate cytotoxicity of CAR-T cells in diffuse large B-cell lymphoma;Aging;2024-01-22